PROTAGONIST THERAPEUTICS, INC. — Income Charts
2 years of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue
$46M
R&D
$159M
D&A
$1M
Operating Income
$-158M
EBITDA
$-157M
Interest Expense
—
Interest Income
$29M
Other Income/Expense
$27K
Pretax Income
$-129M
Tax Provision
$838K
Net Income
$-130M
Operating Margin
-343.6%
Net Margin
-282.8%
Effective Tax Rate
-0.6%
Deferred Tax Assets
—
DTA Valuation Allowance
$167M
Tax Credit Carryforwards
$52M
NOL Carryforwards
$54M
ETR (Continuing Operations)
-0.6%
ETR Federal Statutory
21.0%
ETR State + Local (pp)
-0.6%
ETR Foreign Differential (pp)
—
Operating Lease Cost
$2M
Revenue YoY Variation
-89.4%
Income YoY Variation
-162.5%